References of "DETRY, Olivier"
     in
Bookmark and Share    
Full Text
See detailLa maladie du Renard Wallon!
DETRY, Olivier ULg

Conference (2017, May 13)

Detailed reference viewed: 36 (3 ULg)
Full Text
Peer Reviewed
See detail18-Fluoro-deoxyglucose uptake in inflammatory hepatic adenoma: A case report.
Liu, Willy; Delwaide, Jean ULg; BLETARD, Noëlla ULg et al

in World Journal of Hepatology (2017), 9(11), 562-566

Positron emission tomography computed tomography (PET-CT) using 18-Fluoro-deoxyglucose (18FDG) is an imaging modality that reflects cellular glucose metabolism. Most cancers show an uptake of 18FDG and ... [more ▼]

Positron emission tomography computed tomography (PET-CT) using 18-Fluoro-deoxyglucose (18FDG) is an imaging modality that reflects cellular glucose metabolism. Most cancers show an uptake of 18FDG and benign tumors do not usually behave in such a way. The authors report herein the case of a 38-year-old female patient with a past medical history of cervical intraepithelial neoplasia and pheochromocytoma, in whom a liver lesion had been detected with PET-CT. The tumor was laparoscopically resected and the diagnosis of inflammatory hepatic adenoma was confirmed. This is the first description of an inflammatory hepatic adenoma with an 18FDG up-take. [less ▲]

Detailed reference viewed: 18 (4 ULg)
Full Text
See detailLichtenstein procedure under local anaesthesia
DETRY, Olivier ULg

Conference (2017, March 18)

LICHTENSTEIN REPAIR UNDER LOCAL ANAESTHESIA Pr Olivier Detry, Dpt of Abdominal Surgery and Transplantation, CHU Liège, Liège, Belgium. Email: oli.detry@chu.ulg.ac.be Despite many studies confirming the ... [more ▼]

LICHTENSTEIN REPAIR UNDER LOCAL ANAESTHESIA Pr Olivier Detry, Dpt of Abdominal Surgery and Transplantation, CHU Liège, Liège, Belgium. Email: oli.detry@chu.ulg.ac.be Despite many studies confirming the feasibility and the interest of local anaesthesia for inguinal hernia repair [1-3], its use is not generalized amongst abdominal surgeons. The advantages of local anaesthesia are indeed clear, including reduced costs, reduced hospital stay and reduced post operative pain. The success of the procedure depends on the skills and the motivation of the surgeon, of the nursing teams, and of the patient him/herself. Perfect knowledge of the surgical technique and of the regional nerve anatomy is required. The Lichtenstein repair may be easily performed under local anaesthesia, but should be proposed in the early experience to non-obese patients suffering from limited inguinal hernia. It can even be performed by surgical residents [4]. Practically, local anaesthesia requires some patience and quiet in the operative room. Operators should be aware that the action of local anaesthesia is delayed after injection. Local anaesthetics should be buffered [5] and at body temperature at time of injection. Local anaesthetics containing Adrenalin allow longer pain control, with limitation of bleeding and less toxicity. Large and brutal movements should be avoided. Transversus abdominis plane (TAP) block can also be proposed [6]. The surgical and anaesthetic techniques for inguinal hernia repair should be tailored to the specific characteristics of the hernia and of the patient. There is no method of choice that might fit for every patient. References [1] van Veen RN, Mahabier C, Dawson I, Hop WC, Kok NF, Lange JF, et al. Spinal or local anesthesia in lichtenstein hernia repair: a randomized controlled trial. Ann Surg 2008;247:428-433. [2] Verstraete L, Becaus N, Swannet H, Ceelen W, Duchateau L, Speybroeck N. Long term outcome after lichtenstein hernia repair using general, locoregional or local anaesthesia. Acta Chir Belg 2015;115:136-141. [3] Dhankhar DS, Sharma N, Mishra T, Kaur N, Singh S, Gupta S. Totally extraperitoneal repair under general anesthesia versus Lichtenstein repair under local anesthesia for unilateral inguinal hernia: a prospective randomized controlled trial. Surg Endosc 2014;28:996-1002. [4] Paajanen H, Varjo R. Ten-year audit of Lichtenstein hernioplasty under local anaesthesia performed by surgical residents. BMC Surg 2010;10:24. [5] Ball EL, Sanjay P, Woodward A. Comparison of buffered and unbuffered local anaesthesia for inguinal hernia repair: a prospective study. Hernia : the journal of hernias and abdominal wall surgery 2006;10:175-178. [6] Milone M, Di Minno MN, Musella M, Maietta P, Salvatore G, Iacovazzo C, et al. Outpatient inguinal hernia repair under local anaesthesia: feasibility and efficacy of ultrasound-guided transversus abdominis plane block. Hernia : the journal of hernias and abdominal wall surgery 2013;17:749-755. [less ▲]

Detailed reference viewed: 23 (1 ULg)
Full Text
Peer Reviewed
See detailintravenous administration of mesenchymal stream cells modulates renal lipid metabolism in rats
ERPICUM, Pauline ULg; Rowart, Pascal ULg; POMA, Laurence ULg et al

Conference (2017, March 16)

Mesenchymal stromal cells (MSC) have been shown to attenuate renal ischemia/reperfusion (I/R) injury in rodents. Still, the mechanisms of such a nephroprotection remain unclear. Here, rats were ... [more ▼]

Mesenchymal stromal cells (MSC) have been shown to attenuate renal ischemia/reperfusion (I/R) injury in rodents. Still, the mechanisms of such a nephroprotection remain unclear. Here, rats were intravenously infused with MSC (1.5x10^6 cells in 1 ml saline; MSCD-7 group, n=6) or equivalent volume of saline (SD-7 group, n=6) 7 days before kidney sampling. High-throughput RNA sequencing technology was used to compare transcriptomic renal profiles, using TopHat and Cufflinks open-source software tools. A total of 494 and 256 genes were found to be significantly (q-value <.05) down- and up-regulated in mscd-7 versus sd-7 groups, respectively. Hierarchical cluster analysis by “david” “webgestalt” softwares highlighted that the metabolic pathways mostly affected msc included adipogenesis, insulin signalling, fatty acid (fa) biosynthesis, il-6 b-cell receptor il-3 pathway nuclear receptors involved lipid me- tabolism. Real-time qpcr immunoblotting analyses confirmed pivotal enzymes of fa biosynthesis were significantly downregulated group, whereas expression ppar alpha, a transcription factor oxidation, was induced msc. Additional- ly, fat />CD36 – a key regulator of membrane uptake of FA – was increased in MSCD-7 kidneys, with a preferential localization in proximal tubules (PT). As a whole, our data suggest that MSC infusion causes critical modifications of lipid metabolism, including (i) down-regulation of FA biosynthesis; (ii) activation of PPAR alpha pathway, and (iii) prioritization of FA as sources of energy in PT cells, which may eventually prevent lipid peroxidation and attenuate renal I/R damage. [less ▲]

Detailed reference viewed: 24 (8 ULg)
Full Text
Peer Reviewed
See detailAdministration of Third-Party Mesenchymal Stromal Cells at the Time of Kidney Transplantation: Interim Safety Analysis at One-Year Follow-Up
WEEKERS, Laurent ULg; ERPICUM, Pauline ULg; DETRY, Olivier ULg et al

Conference (2017, March 16)

Mesenchymal stromal cells (MSC)-based therapy has been proposed in kidney transplantation (KTx). We report on the 1-year follow-up of an open-label phase I trial using MSC in KTx. On postoperative day 3 ... [more ▼]

Mesenchymal stromal cells (MSC)-based therapy has been proposed in kidney transplantation (KTx). We report on the 1-year follow-up of an open-label phase I trial using MSC in KTx. On postoperative day 3, third-party MSC (~2.0x106/kg) were administered to 7 non-immunized first-transplant recip- ients from deceased donors, under standard immunosuppression (Basiliximab, Tacrolimus, MMF and steroids). No HLA matching was required for MSC donors. Seven comparable KTx recipients were included as controls. Informed consent was obtained. No side-effect was noted at the time of MSC injection. Still, 1 patient with a history of ischemic heart disease had a NSTEMI ~3h after MSC infusion. Ten months after KTx, 1 MSC patient had type B aortic dissection and STEMI. Four MSC patients had at least 1 opportunistic infection, whereas 3 controls had polyoma-BK viremia. At day 14, eGFR in MSC and control groups was 47.1 ± 6.8 and 39.7 ± 5.9 ml/min, respectively (p, 0.05). At 1 year, eGFR in MSC and control groups was 46.5 ± 18.6 and 54.2 ± 16.3 ml/min, respectively (p, 0.42). Per-cause biopsies evidenced 1 bor- derline and 1 acute rejections in MSC group, whereas no AR was biopsy-proven in controls. Three patients developed anti-HLA antibodies against MSC (n=1) or shared kidney/MSC (n=2) mismatches.MSC infusion was safe in all patients except one. Incidence of opportunist infections was similar in both groups. No difference in eGFR was found at 1-year post KTx. Putative immunization against MSC was observed in 3 patients. [less ▲]

Detailed reference viewed: 14 (1 ULg)
Full Text
See detailCancer in the organ donor
DETRY, Olivier ULg

Conference (2017, March 16)

Organ Donation and Cancer Pr Olivier Detry, Dpt of Abdominal Surgery and Transplantation, University of Liege The risk of transmission of cancer with the transplanted organ has been known since the ... [more ▼]

Organ Donation and Cancer Pr Olivier Detry, Dpt of Abdominal Surgery and Transplantation, University of Liege The risk of transmission of cancer with the transplanted organ has been known since the pioneering years of solid organ transplantation, and is enhanced by immunosuppression and particularly the calcineurin inhibitors. Therefore, classically, potential organ donors with past history of cancer are excluded from donation, with the exception of low-grade malignant tumours of the central nervous system, the skin and the cervix uteri. Despite that policy, every year, some cases of cancer transmission with organ transplantation were regularly reported in transplant medical journals. At the other hand, there is a clear graft shortage, with long organ transplant waiting lists and inacceptable mortality while waiting for a life saving graft. One mean to increase the number of available grafts could be to accept donation from donors with past history of cancer. Several uncertainties remain: what is the risk of cancer transmission with organ transplantation? This risk depends of course of many donor factors, as the staging and the nature of the donor malignant tumour, the oncological management, the delay between the remission and the organ procurement. This risk may also vary according to the type of organ transplanted, as livers and lungs are more prone to bear occult metastases, compared to the hearts for example. In fact, this risk is unknown, and was clearly overestimated by the old registries as the IPTR, and by the various case reports. All modern prospective registries, as from UNOS or from UK transplant, now report a very low rate of cancer transmission when the donor cancer was known and evaluated before organ donation. Undiagnosed or occult cancer transmission with transplantation is clearly another issue that should not be mistaken with the donors with past history of cancer. In most of the recent reported cases of cancer transmission with transplantation, the donor cancer was not diagnosed before and during organ donation. And this risk increases in modern organ transplantation, as we are now accepting older and older donors, particularly in transplantation of the liver, an organ particularly at risk of metastases. Therefore surgical donor exploration is an important step of organ procurement. Body CT could be a tool to diagnose some, but not all, of these tumours. To my view, the risk of cancer transmission with transplantation has to be balanced with the risk of dying on the waiting lists. Donors with active or recent aggressive cancers have to be excluded from donation. Some types of aggressive cancers, as lymphoma or melanoma, are at high risk. In donors with past history of cancer with some years of remission, organ donation should be considered for recipients at high risk of death without a rapid transplantation. Particularly, heart transplantation, an organ with a low risk of cancer transmission but with a severe organ shortage, could benefit from such a policy. [less ▲]

Detailed reference viewed: 23 (1 ULg)
Full Text
See detailLes éventrations parastomales: prévention et traitement
DETRY, Olivier ULg

Scientific conference (2017, February 24)

Detailed reference viewed: 16 (1 ULg)
Full Text
Peer Reviewed
See detailUNE INJECTION UNIQUE DE CELLULES STROMALES MESENCHYMATEUSES AU JOUR 3 APRES GREFFE HEPATIQUE EST INSUFFISANTE POUR INDUIRE UNE TOLERANCE OPERATIONNELLE
DETRY, Olivier ULg; VANDERMEULEN, Morgan ULg; DELBOUILLE, Marie-Hélène ULg et al

in Transplant International (2017, January), 30(suppl 1), 812

Introduction: Mesenchymal stromal cell (MSC) infusion could be a mean to establish donor-specific immunological tolerance in solid organ recipients. The aim of this phase 2 study was test the hypothesis ... [more ▼]

Introduction: Mesenchymal stromal cell (MSC) infusion could be a mean to establish donor-specific immunological tolerance in solid organ recipients. The aim of this phase 2 study was test the hypothesis of possible induction of operative tolerance by third-party MSC in liver transplant (LT) recipients. Methods: 10 stable and low-risk LT recipients under standard immunosup- pression (Tac-MMF- low dose steroids) received 1.5–3 9 106/kg third-party MSCs on post-operative day 3 ` 2. By protocol, progressive weaning of immunosuppression was attempted in patients who did not develop rejection and had normal graft function and month-6 graft biopsy. Tacrolimus was progressively tapered from day 180 to be discontinued by day 270. After day- 270 graft biopsy, MMF was progressively tapered and definitely discontinued by day 365 in the absence of rejection. Results: One patient from the MSC group was excluded from immunosup- pression withdrawal attempt due to HCC recurrence, and the 9 others met the necessary criteria. In one patient, tacrolimus and MMF withdrawal was performed without rejection. In two patients, MMF monotherapy was achieved at month 9, but graft rejection occurred during MMF withdrawal and was successfully treated by tacrolimus reintroduction. In 6 patients, the transam- inases significantly increased during tacrolimus withdrawal. In these cases, withdrawal was cancelled and liver tests normalised after increase of the tacrolimus dose. No graft was lost due to the withdrawal attempt. Conclusion: A single post transplant MSC injection is not sufficient to induce operative tolerance after LT. [less ▲]

Detailed reference viewed: 21 (6 ULg)
Full Text
Peer Reviewed
See detailUne série consécutive de 125 greffes hépatiques à partir de donneurs cadavériques en mort circulatoire
DETRY, Olivier ULg; MEURISSE, Nicolas ULg; HANS, Marie-France ULg et al

in Transplant International (2017, January), 30(Suppl 1), 2481

Introduction: Donation after circulatory death (DCD) has been proposed to partially overcome the organ donor shortage. DCD-LT remains controversial, with reported increased risk of graft loss and ... [more ▼]

Introduction: Donation after circulatory death (DCD) has been proposed to partially overcome the organ donor shortage. DCD-LT remains controversial, with reported increased risk of graft loss and retransplantation. The authors retrospectively reviewed a single centre experience with controlled DCD-LT in a 14-year period. Patients and Methods: 125 DCD-LT were consecutively performed between 2003 and 2016. All donation and procurement procedures were performed as controlled DCD in operative rooms. Data are presented as median (ranges). Median donor age was 56 years (16–84). Most grafts were flushed with HTK solution in the first part of experience, and more recently with IGL1. Allocation was centre-based. Median follow-up was 52 (1–164) months. No patient was lost to follow-up. Results: Median total DCD warm ischemia was 19 min (9–39). Median cold ischemia was 238 min (105–576). Patient survivals were 90.2%, 77.5% and 74.5 % at 1.3 and 5 years, respectively. Graft survivals were 87.7%, 76.3% and 73.2% at 1.3 and 5 years, respectively. Biliary complications included anas- tomotic strictures and extrahepatic main bile duct ischemic obstruction, that were managed either by endoscopy or hepatico-jejunostomy. No PNF was observed in this series and one graft was lost due to ischemic cholangiopathy. Discussion: In this series, DCD LT appears to provide results similar to classical LT. Short cold ischemia and recipient selection with low MELD score may be the keys to good results in DCD LT, in terms of graft survival and avoidance of ischemic cholangiopathy. [less ▲]

Detailed reference viewed: 23 (7 ULg)
Full Text
Peer Reviewed
See detailThe use of mesenchymal stromal cells in solid organ transplantation
GREGOIRE, Céline ULg; DETRY, Olivier ULg; Jouret, François ULg et al

in The Biology and Therapeutic Application of Mesenchymal Cells (2017)

Detailed reference viewed: 112 (66 ULg)
Full Text
Peer Reviewed
See detailInfusion of mesenchymal stromal cells after deceased liver transplantation: A phase I-II, open-label, clinical study.
DETRY, Olivier ULg; VANDERMEULEN, Morgan ULg; DELBOUILLE, Marie-Hélène ULg et al

in Journal of Hepatology (2017)

BACKGROUND & AIM: Mesenchymal stromal cell (MSC) infusion could be a mean to establish tolerance in solid organ recipients. The aim of this prospective, controlled, phase-1 study was to evaluate the ... [more ▼]

BACKGROUND & AIM: Mesenchymal stromal cell (MSC) infusion could be a mean to establish tolerance in solid organ recipients. The aim of this prospective, controlled, phase-1 study was to evaluate the feasibility, safety and tolerability of a single infusion of MSCs in liver transplant recipients. METHODS: Ten liver transplant recipients under standard immunosuppression received 1.5-3x106/kg third-party unrelated MSCs on post-operative day 3+/-2, and were prospectively compared to a control group of 10 liver transplant recipients. As primary end-points, MSC infusional toxicity was evaluated, and infectious and cancerous complications were prospectively recorded until month 12 in both groups. As secondary end-points, rejection rate, month-6 graft biopsies, and peripheral blood lymphocyte phenotyping were compared. Progressive immunosuppression weaning was attempted from month 6 to 12 in MSC recipients. RESULTS: No variation in vital parameters or cytokine release syndrome could be detected during and after MSC infusion. No patient developed impairment of organ functions (including liver graft function) following MSC infusion. No increased rate of opportunistic infection or de novo cancer was detected. As secondary end-points, there was no difference in overall rates of rejection or graft survival. Month-6 biopsies did not demonstrate a difference between groups in the evaluation of rejection according to the Banff criteria, in the fibrosis score or in immunohistochemistry (including Tregs). No difference in peripheral blood lymphocyte typing could be detected. The immunosuppression weaning in MSC recipients was not successful. CONCLUSIONS: No side effect of MSC infusion at day 3 after liver transplant could be detected, but this infusion did not promote tolerance. This study opens the way for further MSC or Treg-based trials in liver transplant recipients. LAY SUMMARY: Therapy with mesenchymal stromal cells (MSCs) has been proposed as a mean to improve results of solid organ transplantation. One of the potential MSC role could be to induce tolerance after liver transplantation, i.e. allowing the cessation of several medications with severe side effects. This study is the first-in-man use of MSC therapy in 10 liver transplant recipients. This study did not show toxicity after a single MSC infusion but it was not sufficient to allow withdrawal of immunosuppression. [less ▲]

Detailed reference viewed: 53 (12 ULg)
Full Text
Peer Reviewed
See detailSepramesh and postoperative peritoneal adhesions in a rat model
Arung, Willy; Drion, Pierre ULg; DETRY, Olivier ULg

in Acta Chirurgica Belgica (2016), 116(6), 357-361

Purpose: The present study aimed to investigate the safety and the anti-postoperative peritoneal adhesion (PPA) characteristics of SeprameshVR (Davol), a composite mesh made of polypropylene covered with ... [more ▼]

Purpose: The present study aimed to investigate the safety and the anti-postoperative peritoneal adhesion (PPA) characteristics of SeprameshVR (Davol), a composite mesh made of polypropylene covered with Seprafilm, when intraperitoneally placed in a rat model. Methods: Twenty male rats were randomized into a control group and a Sepramesh group. They underwent a primary surgical procedure aiming to induce a peritoneal injury in order to induce PPAs. In the Sepramesh group, the burnt peritoneum was covered with a 2-cm diameter disc of Sepramesh prosthesis. The mesh was fixed to the parietal peritoneum with four 3-0 absorbable stitches. PPAs were assessed during a second laparotomy 10 days later using quantitative and qualitative scoring systems. Results: There was no difference in terms of mean number of PPAs between both groups. All the rats from the control group developed PPAs. In the Sepramesh group, no adhesions were observed at the site of the injured peritoneum that had been covered with the Sepramesh prosthesis, but PPAs occurred at the extremities of the mesh, where there was close contact between polypropylene and viscera, or where the fixation sutures were placed. The severity and the type of adhesions were significantly higher in the control group. Conclusions: This study demonstrated that for the Sepramesh prostheses, the Seprafilm layer might be effective in PPA prevention, but damage caused by the section and fixation of Sepramesh should be limited in order to limit PPAs. [less ▲]

Detailed reference viewed: 26 (4 ULg)
Full Text
See detailChirurgie abdominale et transplantation: actualités et avenir
DETRY, Olivier ULg

Scientific conference (2016, November 19)

Detailed reference viewed: 15 (2 ULg)
Full Text
Peer Reviewed
See detailLongterm results of liver transplantation from donation after circulatory death.
Blok, Joris J.; DETRY, Olivier ULg; Putter, Hein et al

in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society (2016), 22(8), 1107-14

Donation after circulatory death (DCD) liver transplantation (LT) may imply a risk for decreased graft survival, caused by posttransplantation complications such as primary nonfunction or ischemic-type ... [more ▼]

Donation after circulatory death (DCD) liver transplantation (LT) may imply a risk for decreased graft survival, caused by posttransplantation complications such as primary nonfunction or ischemic-type biliary lesions. However, similar survival rates for DCD and donation after brain death (DBD) LT have been reported. The objective of this study is to determine the longterm outcome of DCD LT in the Eurotransplant region corrected for the Eurotransplant donor risk index (ET-DRI). Transplants performed in Belgium and the Netherlands (January 1, 2003 to December 31, 2007) in adult recipients were included. Graft failure was defined as either the date of recipient death or retransplantation whichever occurred first (death-uncensored graft survival). Mean follow-up was 7.2 years. In total, 126 DCD and 1264 DBD LTs were performed. Kaplan-Meier survival analyses showed different graft survival for DBD and DCD at 1 year (77.7% versus 74.8%, respectively; P = 0.71), 5 years (65.6% versus 54.4%, respectively; P = 0.02), and 10 years (47.3% versus 44.2%, respectively; P = 0.55; log-rank P = 0.038). Although there was an overall significant difference, the survival curves almost reach each other after 10 years, which is most likely caused by other risk factors being less in DCD livers. Patient survival was not significantly different (P = 0.59). Multivariate Cox regression analysis showed a hazard ratio of 1.7 (P < 0.001) for DCD (corrected for ET-DRI and recipient factors). First warm ischemia time (WIT), which is the time from the end of circulation until aortic cold perfusion, over 25 minutes was associated with a lower graft survival in univariate analysis of all DCD transplants (P = 0.002). In conclusion, DCD LT has an increased risk for diminished graft survival compared to DBD. There was no significant difference in patient survival. DCD allografts with a first WIT > 25 minutes have an increased risk for a decrease in graft survival. Liver Transplantation 22 1107-1114 2016 AASLD. [less ▲]

Detailed reference viewed: 13 (2 ULg)
Full Text
See detailL'insuffisance hépatique
DETRY, Olivier ULg

Scientific conference (2016, June 16)

Detailed reference viewed: 29 (4 ULg)
Full Text
See detailHépatocarcinome: Place de la chirurgie
DETRY, Olivier ULg

Conference given outside the academic context (2016)

Detailed reference viewed: 26 (0 ULg)